Menu

BeyondSPX has rebranded as EveryTicker. We now operate at everyticker.com, reflecting our coverage across nearly all U.S. tickers. BeyondSPX has rebranded as EveryTicker.

Everest Re Group, Ltd. (EG)

$332.70
-1.41 (-0.42%)
Get curated updates for this stock by email. We filter for the most important fundamentals-focused developments and send only the key news to your inbox.

Data provided by IEX. Delayed 15 minutes.

Company Profile

Price Chart

Loading chart...

At a glance

Balance Sheet Surgery in Progress: Everest is aggressively excising its U.S. casualty cancer through $2.2 billion in reserve additions, a $1.2 billion adverse development cover, and exiting $2 billion in global retail insurance—actions that will either cure the patient or reveal deeper malignancy by 2026.

Reinsurance: The Hidden Gem: The Reinsurance segment delivered an 87% combined ratio in Q3 2025 while competitors struggle with cat volatility, generating over $100 million in underwriting income from Global Specialties alone—a business that should command a premium valuation but remains obscured by insurance segment losses.

Capital Inflection Point: The AIG (AIG) renewal rights sale and ADC transaction will release "meaningful total value" and "significant capital" according to management, funding a buyback program that has already repurchased $400 million year-to-date at prices below current book value—a clear signal of value recognition.